Reductions in malaria in pregnancy and adverse birth outcomes following indoor residual spraying of insecticide in Uganda. by Muhindo, Mary K et al.
LSHTM Research Online
Muhindo, Mary K; Kakuru, Abel; Natureeba, Paul; Awori, Patricia; Olwoch, Peter; Ategeka, John;
Nayebare, Patience; Clark, Tamara D; Muehlenbachs, Atis; Roh, Michelle; +6 more... Mpeka, Betty;
Greenhouse, Bryan; Havlir, Diane V; Kamya, Moses R; Dorsey, Grant; Jagannathan, Prasanna;
(2016) Reductions in malaria in pregnancy and adverse birth outcomes following indoor resid-
ual spraying of insecticide in Uganda. MALARIA JOURNAL, 15 (1). ISSN 1475-2875 DOI:
https://doi.org/10.1186/s12936-016-1489-x
Downloaded from: http://researchonline.lshtm.ac.uk/4652809/
DOI: https://doi.org/10.1186/s12936-016-1489-x
Usage Guidlines:
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
https://researchonline.lshtm.ac.uk
Muhindo et al. Malar J  (2016) 15:437 
DOI 10.1186/s12936-016-1489-x
RESEARCH
Reductions in malaria in pregnancy 
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Abstract 
Background: Indoor residual spraying of insecticide (IRS) is a key intervention for reducing the burden of malaria in 
Africa. However, data on the impact of IRS on malaria in pregnancy and birth outcomes is limited.
Methods: An observational study was conducted within a trial of intermittent preventive therapy during pregnancy 
in Tororo, Uganda. Women were enrolled at 12–20 weeks of gestation between June and October 2014, provided with 
insecticide-treated bed nets, and followed through delivery. From December 2014 to February 2015, carbamate-con-
taining IRS was implemented in Tororo district for the first time. Exact spray dates were collected for each household. 
The exposure of interest was the proportion of time during a woman’s pregnancy under protection of IRS, with three 
categories of protection defined: no IRS protection, >0–20 % IRS protection, and 20–43 % IRS protection. Outcomes 
assessed included malaria incidence and parasite prevalence during pregnancy, placental malaria, low birth weight 
(LBW), pre-term delivery, and fetal/neonatal deaths.
Results: Of 289 women followed, 134 had no IRS protection during pregnancy, 90 had >0–20 % IRS protection, and 
65 had >20–43 % protection. During pregnancy, malaria incidence (0.49 vs 0.10 episodes ppy, P = 0.02) and parasite 
prevalence (20.0 vs 8.9 %, P < 0.001) were both significantly lower after IRS. At the time of delivery, the prevalence of 
placental parasitaemia was significantly higher in women with no IRS protection (16.8 %) compared to women with 
0–20 % (1.1 %, P = 0.001) or >20–43 % IRS protection (1.6 %, P = 0.006). Compared to women with no IRS protection, 
those with >20–43 % IRS protection had a lower risk of LBW (20.9 vs 3.1 %, P = 0.002), pre-term birth (17.2 vs 1.5 %, 
P = 0.006), and fetal/neonatal deaths (7.5 vs 0 %, P = 0.03).
Conclusion: In this setting, IRS was temporally associated with lower malaria parasite prevalence during pregnancy 
and at delivery, and improved birth outcomes. IRS may represent an important tool for combating malaria in preg-
nancy and for improving birth outcomes in malaria-endemic settings.
Trial Registration Current Controlled Trials Identifier NCT02163447
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Background
In sub-Saharan Africa, over 30 million pregnancies occur 
annually in areas where malaria is endemic, and each 
year malaria in pregnancy is estimated to cause nearly 
one million low birth weight (LBW) deliveries and up 
to 100,000 infant deaths [1–3]. Given this high burden 
of disease, the World Health Organization (WHO) rec-
ommends the implementation of malaria preventive 
measures in all African countries where Plasmodium 
falciparum remains endemic, including the use of long-
lasting, insecticide-treated nets (LLINs) and intermittent 
preventive treatment during pregnancy (IPTp) with sulf-
adoxine-pyrimethamine (SP) [4].
Despite these measures, rates of placental malaria and 
poor birth outcomes remain persistently high in many 
parts of Africa. In a recent cross-sectional study per-
formed in Tororo, a highly endemic district in Uganda 
where nearly 70  % of pregnant women reported using 
a LLIN, the prevalence of placental malaria was 62 % in 
women who had received ≥two doses of IPTp-SP, and 
nearly 10 % of children were born with LBW [5]. This and 
other studies have raised concern for waning efficacy of 
LLINs given the emergence of resistance to pyrethroid 
insecticides [6–8], as well as waning efficacy of SP given 
widespread prevalence of drug-resistant parasites [9]. 
New interventions to prevent malaria during pregnancy 
and improve birth outcomes are urgently needed.
Indoor residual spraying (IRS) has been shown to 
be very effective in reducing vector densities, parasite 
prevalence and malaria morbidity in sub-Saharan Africa 
[10–14]. IRS can provide significant added protection 
together with LLINs compared to LLINs alone, particu-
larly in areas with significant pyrethroid resistance [15–
18], although evidence has been mixed [19, 20]. In 2006, 
Uganda began using IRS in selected districts, initially in 
the epidemic-prone areas of southwestern Uganda but 
later in the highly endemic areas of northern Uganda, 
with significant reductions in malaria morbidity and 
slide positivity rates [10, 14]. However, data quantifying 
the impact of IRS on malaria in pregnancy and birth out-
comes are lacking.
Recently, a clinical trial was conducted comparing IPTp 
with dihydroartemisinin-piperaquine (DP) with IPTp-SP 
among HIV-uninfected pregnant women. This study was 
conducted in Tororo, Uganda, where, in separate studies, 
the East African International Centres of Excellence in 
Malaria Research (ICEMR) have been conducting cohort 
studies and entomology surveys since 2011 [21]. IPTp-
DP was well tolerated, and significantly reduced parasite 
prevalence during pregnancy and the risk of placental 
malaria [22]. Midway through this trial, the President’s 
Malaria Initiative (PMI), through its implementing part-
ner Abt Associates, initiated IRS in Tororo district for 
the first time [23]. Measures of malaria during pregnancy 
were compared before and after the implementation 
of IRS, and associations between IRS exposure during 
pregnancy and adverse birth outcomes were evaluated, 
among participants enrolled in this trial.
Methods
Study site and participants
Tororo is a rural district in southeastern Uganda with an 
entomologic inoculation rate estimated at 310 infectious 
bites per person year in 2012 [21]. Following a universal 
LLIN distribution campaign in November 2013 [23], 95 % 
of household in the region reported owning at least one 
LLIN [24]. Between June and October 2014, 300 women 
were enrolled into a double-blinded, placebo-controlled 
trial of three-dose SP vs three-dose DP vs monthly DP 
for IPTp. Details of the parent study have been described 
elsewhere [22]. Briefly, participants were HIV-uninfected 
pregnant women at least 16 years of age of all gravidities 
with an estimated gestational age of 12–20  weeks con-
firmed by ultrasound. The sub-study described in this 
report includes all women followed through delivery 
(n = 289).
From December 2014 to February 2015, Abt, in coop-
eration with the Ugandan Ministry of Health, initiated 
IRS in Tororo district using bendiocarb wettable powder, 
a carbamate insecticide [23]. Homes were sprayed once 
and following spraying, houses were marked with the 
date of spraying. Home visitors obtained the exact date 
of spraying from each participant’s household. If a house-
hold was not sprayed, the reasons for a lack of spraying 
were obtained and if the surrounding households in the 
village were sprayed, the date of spraying was obtained 
from surrounding homes.
Study procedures and follow‑up
At enrolment, women underwent a standardized exami-
nation and received a LLIN. Study participants were ran-
domized in a 1:1:1 ratio to three-dose SP vs three-dose 
DP vs monthly DP for IPTp, as previously described [22]. 
Women received all of their medical care at a study clinic 
open daily. Routine visits were conducted every 4 weeks, 
including collection of dried blood spots (DBS). Women 
were encouraged to come to the clinic any time they were 
ill. Those who presented with a documented fever (tym-
panic temperature >38.0 °C) or history of fever in the pre-
vious 24 h had blood collected for a thick blood smear. If 
the smear was positive, the patient was diagnosed with 
malaria and treated with artemether-lumefantrine.
Women were encouraged to deliver at the hospital 
adjacent to the study clinic. Women delivering at home 
were visited by study staff at the time of delivery or as 
soon as possible afterwards. At delivery a standardized 
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assessment was completed, including evaluation for birth 
weight and collection of specimens, including placental 
tissue and DBS of placental blood.
Laboratory methods
DBS were tested for the presence of malaria parasites 
using loop-mediated isothermal amplification (LAMP) 
[25]. Placental tissues were processed for histological 
evidence of placental malaria as previously described 
[22]. Histopathology slides were read in duplicate using 
a standardized case record form by two independent 
readers and any discrepant results resolved by a third 
reader. Blood smears were collected in febrile women 
during pregnancy, stained with 2 % Giemsa and read by 
laboratory technologists. A blood smear was considered 
negative when the examination of 100 high power fields 
did not reveal asexual parasites. All slides were read by a 
second microscopist and a third reviewer settled any dis-
crepant readings.
Entomological surveys
Entomological surveys were conducted monthly begin-
ning in June 2011 from 100 households enrolled in a 
separate longitudinal cohort study in Nagongera sub-
county, Tororo district, as part of the ICEMR programme 
in Uganda [21]. Each month, miniature CDC light traps 
(Model 512; John W Hock Company, Gainesville, FL, 
USA) were positioned with the light 1 m above the floor 
at the foot end of the bed where a cohort study par-
ticipant slept. Traps were set at 19.00 and collected at 
07.00 h the following morning by field workers.
Primary exposure variable
A woman was considered ‘protected under IRS’ if her 
house was directly sprayed, or if the surrounding village 
was sprayed, 14  days after spraying to account for the 
average incubation period for P. falciparum. The dura-
tion of pregnancy under protection of IRS was calcu-
lated as the date of delivery—(date of IRS + 14 days). The 
total duration of pregnancy was calculated as the date 
of delivery—estimated date of conception (ultrasound-
confirmed). The proportion of time during a woman’s 
pregnancy that was under protection of IRS was then 
calculated as the duration of pregnancy under IRS/total 
duration of pregnancy. Three categories of protection 
were defined: no protection, >0–20 % of pregnancy pro-
tected, and >20–43 % of pregnancy protected.
Outcomes
Outcomes assessed during pregnancy included parasite 
prevalence by LAMP and the incidence of malaria, calcu-
lated as the number of episodes per person years (ppy) at 
risk. Outcomes assessed at birth included the prevalence 
of parasitaemia at delivery by LAMP and evidence of 
placental malaria (parasites or pigment) by histopathol-
ogy. Placental histopathology was also classified accord-
ing to whether moderate-high grade pigment deposition 
was present (defined as pigment detected in >5  % of 
high power 40× fields) [26]. Birth outcomes assessed 
included birth weight, LBW (<2500 g), pre-term delivery 
(<37  weeks), and fetal/neonatal deaths, including spon-
taneous abortion, stillbirth and neonatal death within 
4  weeks of delivery. For women giving birth to twins, 
delivery outcomes were based on whether the outcome 
was present in either child/placenta.
Statistical methods
Data were double entered into an Access database. Data 
analysis was done using Stata version 14 (Stata Corp, Col-
lege Station, TX, USA). Baseline characteristics between 
groups were compared using the χ2 test. Repeated prev-
alence measures and the daily risk of malaria during 
pregnancy were compared using generalized estimating 
equations with a log-binomial family, after adjustment for 
gravidity, age, IPTp arm, and gestational age when study 
drugs were started, and presented as adjusted risk ratios 
(aRR). For results stratified by IPTp arm, women rand-
omized to either IPTp-DP arm were considered together. 
Dichotomous outcomes at delivery were compared using 
multivariate logistic regression. Continuous outcomes at 
delivery were compared using multivariate linear regres-
sion, with adjustment as above. As a secondary sensitiv-
ity analysis, propensity scores and inverse probability 
weighting were used to assess the average causal effect 
of IRS exposure with outcomes at delivery. All P-values 
were two-sided and values <0.05 considered statistically 
significant.
Results
Characteristics of study site and participants
Between June and October 2014, 300 women were 
enrolled prior to IRS, and 289 women were followed 
through delivery from October 2014 to May 2015 (Fig. 1). 
From December 2014 to February 2015, 123,924 of 
145,574 households (85.1  %) in Tororo district received 
IRS. Among women in the study cohort, 95 % of house-
holds were sprayed between 1 December, 2014 and 31 
January, 2015, with the remaining sprayed in February 
2015. Monthly measurements of female Anopheles mos-
quitoes collected per household per night in Tororo were 
lower from February to May 2015, after IRS, compared 
with February–May 2014 (5.4 vs 33.7 female Anopheles 
mosquitoes per house per night, P < 0.001) (Fig. 1).
Of 289 women followed through delivery, 155 (53.6 %) 
were exposed to IRS before the birth of their child; 137 
of these women’s households were directly sprayed, and 
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18 households (11.6 %) were indirectly protected through 
spraying of the surrounding village. Of the 134 women 
not exposed to IRS during pregnancy, six lived outside 
of the IRS spraying area in neighbouring Busia district, 
and 128 were exposed to IRS after the birth of their 
child. The median duration of pregnancy under protec-
tion of IRS was 46  days (IQR 20–68  days), and women 
were stratified into three groups based on the proportion 
of pregnancy under the protection of IRS: 0 (n =  134), 
>0–20 % (n = 90), and >20–43 % (n = 65). At enrolment, 
the prevalence of malaria parasites was >55 % and simi-
lar between the three groups (Table 1). Women with no 
IRS protection during pregnancy were slightly younger, 
more likely primigravid, and more likely to have study 
drugs initiated at 20 weeks gestation vs 16 weeks gesta-
tion, than women with IRS protection during pregnancy. 
IPTp treatment assignments, maternal weight gain, and 
household wealth were similar between groups (Table 1).
Malaria incidence and parasite prevalence 
during pregnancy, before and after IRS
Parasite prevalence at enrolment and before study drug 
initiation was stable and high prior to IRS (see Addi-
tional file 1). After study drug initiation, the incidence of 
malaria during pregnancy was significantly higher before 
IRS (0.49 episodes ppy) compared to after IRS (0.10 
episodes ppy, aRR 0.20, P  =  0.02) after adjustment for 
gravidity, age, IPTp arm, and gestational age when study 
drugs were started. Similarly, the prevalence of malaria 
parasites by LAMP during pregnancy was significantly 
higher before IRS (20.0 %) compared to after IRS (8.9 %, 
aRR 0.40, P < 0.001). Declines were observed in women 
randomized to both IPTp-SP and IPTp-DP, although 
there was evidence of interaction between IPTp and IRS 
(P =  0.07, Fig.  2). Among women randomized to IPTp-
SP, the prevalence of parasitaemia was 44.0 % before IRS, 
before declining to 22.0 % after IRS (aRR 0.49, P = 0.003). 
Among women randomized to IPTp-DP, parasite preva-
lence was 8.7 % before IRS vs 1.1 % after IRS (aRR 0.13, 
P = 0.003). Women living in households directly sprayed 
vs those indirectly sprayed were both protected by IRS. 
Among women living in households directly sprayed, 
parasite prevalence was 20.2 % before IRS vs 8.5 % after 
IRS (aRR 0.42, 95  % CI 0.26–0.70, P  =  0.001). Among 
women living in households indirectly sprayed, parasite 
prevalence was 34.2 % before IRS vs 5.0 % after IRS (aRR 
0.12, 95 % CI 0.03–0.59, P = 0.009), consistent with com-
munity-wide benefits of IRS on parasitaemia [11].
Association between IRS and placental malaria
At delivery, the prevalence of malaria parasites in placen-
tal blood by LAMP was significantly higher in women 
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with no IRS protection (16.8  %) compared to women 
with >0–20 % (1.1 %, P = 0.001) or >20–43 % IRS protec-
tion during pregnancy (1.6 %, P = 0.006) (Table 2). The 
prevalence of any placental malaria by histopathology, as 
well as the prevalence of moderate to high-grade pigment 
deposition, was higher in women with no IRS protection 
compared with women with IRS protection (Table  2), 
but the differences were not statistically significant. All 
Table 1 Characteristics of women stratified by duration of pregnancy under the protection of IRS
a P < 0.001
Characteristic Proportion of pregnancy under the protection of IRS
None (n = 134) >0–20 % (n = 90) >20–43 % (n = 65)
Malaria parasites detected at enrolment, n (%) 76 (56.7 %) 52 (57.8 %) 39 (60.0 %)
Age at enrolment in years, mean (SD)a 21.1 (3.9) 22.9 (4.0) 22.6 (4.0)
Gravidity, n (%)a
 1 64 (47.8 %) 23 (25.6 %) 16 (24.6 %)
 2 37 (27.6 %) 25 (27.8 %) 25 (38.5 %)
 >3 33 (24.6 %) 42 (46.7 %) 24 (36.9 %)
Study drugs started at 16 vs 20 weeks GA, n (%)a 61 (45.5 %) 85 (94.4 %) 57 (87.7 %)
Assigned IPTp arm, n (%)
 3-dose SP 45 (33.6 %) 34 (37.8 %) 23 (35.4 %)
 3-dose DP 41 (30.6 %) 26 (28.9 %) 22 (33.9 %)
 Monthly DP 48 (35.8 %) 30 (33.3 %) 20 (30.8 %)
Maternal weight gain during pregnancy, mean  
kg/week (SD)
0.25 (0.15) 0.25 (0.12) 0.24 (0.15)
Household wealth index, n (%)
 Lowest tertile 45 (33.6 %) 34 (37.8 %) 20 (30.8 %)
 Middle tertile 45 (33.6 %) 23 (25.6 %) 27 (41.5 %)
 Highest tertile 44 (32.8 %) 33 (36.7 %) 18 (27.7 %)
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Fig. 2 Parasite prevalence during pregnancy by calendar month before, during and after IRS. Shown is the predicted probability of having a posi-
tive (+) LAMP result during pregnancy, stratified by IPTp arm, after enrolment and initiation of study drugs, over the period of time of the study. 
Parasite prevalence point estimates and standard errors obtained using generalized estimating equations after adjustment for gravidity, age, and 
gestational age when study drugs were started. Grey-shaded bar shows the time period of IRS in Tororo district. SP (black): sulfadoxine-pyrimeth-
amine; DP (blue): dihydroartemisinin-piperaquine
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105 placentas that were positive for placental malaria by 
histopathology had pigment in fibrin that was indicative 
of past infection, and seven (11 %) had parasites indica-
tive of concomitant active infection. All seven with active 
infection were not exposed to IRS prior to delivery.
Association between IRS and birth outcomes
The prevalence of LBW was significantly higher in 
infants born to mothers with no IRS protection (20.9 %) 
compared to those with >0–20  % (10.0  %, P =  0.01) or 
>20–43  % IRS protection (3.1  %, P  =  0.002) (Table  2). 
Compared to infants born to women with no IRS protec-
tion, mean birth weight was 196 g higher among infants 
born to women with 0–20  % IRS protection (95  % CI 
51–340  g, P  =  0.008) and 257  g higher among infants 
born to women with >20–43 % IRS protection (95 % CI 
105–409 g, P = 0.001) (Fig. 3). When restricting the anal-
ysis to women without histologic evidence of placental 
malaria, the prevalence of LBW was similarly higher in 
infants born to mothers with no IRS protection (18.8 %) 
compared to those with >0–20  % (7.9  %, P  =  0.07) or 
>20–43 % IRS protection (2.2 %, P = 0.03).
The prevalence of pre-term birth was significantly 
higher in infants born to women with no IRS protec-
tion (17.2  %) compared to those with >0–20  % (3.3  %, 
P = 0.01) or >20–43 % IRS protection (1.5 %, P = 0.006) 
(Table 2). Of 11 fetal/neonatal deaths (three spontaneous 
abortions, three still births, and five neonatal deaths), 
ten (7.5  % of pregnancies) occurred among those with 
no IRS protection, and none occurred among those with 
20–43  % IRS protection (P  =  0.03). Given the imbal-
ances noted between IRS protection strata, a sensitivity 
analysis was performed to evaluate associations between 
IRS and outcomes at delivery using propensity scores 
with inverse probability weighting, with similar results 
(see Additional file 2). In all analyses, there was no sig-
nificant interaction observed between IRS and assigned 
IPTp group.
Table 2 Associations between proportion of pregnancy under the protection of IRS and outcomes measured at birth
LBW low birth weight; aOR adjusted odds ratio
a Includes all subjects with evaluable outcomes of interest
b Odds ratio adjusted for gravidity, household wealth, presence of parasites at enrollment, gestational age study drugs started, and assigned IPTp treatment arm
Outcome Proportion of pregnancy under the protection of IRS
None >0–20 % >20–43 %
Placental blood positive for malaria parasites by LAMPa
 Risk 22/131 (16.8 %) 1/88 (1.1 %) 1/61 (1.6 %)
 aORb (95 % CI) Reference group 0.03 (0–0.25) 0.05 (0.01–0.41)
 P value 0.001 0.006
Any evidence of placental malaria by histopathologya
 Risk 63/132 (47.7 %) 25/88 (28.4 %) 17/62 (27.4 %)
 aORb (95 % CI) Reference group 0.77 (0.35–1.69) 0.63 (0.27–1.48)
 P value 0.51 0.29
Moderate-high grade pigment deposition by histopathologya
 Risk 37/132 (28.0 %) 11/88 (12.5 %) 9/62 (14.5 %)
 aORb (95 % CI) Reference group 0.52 (0.20–1.36) 0.54 (0.20–1.47)
 P value 0.18 0.23
 Risk 28/134 (20.9 %) 9/90 (10.0 %) 2/65 (3.1 %)
LBW (<2500 g)
 aORb (95 % CI) Reference group 0.29 (0.12–0.75) 0.08 (0.02–0.39)
 P value 0.01 0.002
 Risk 23/134 (17.2 %) 3/90 (3.3 %) 1/65 (1.5 %)
Pre-term delivery (<37 weeks)
 aORb (95 % CI) Reference group 0.13 (0.03–0.53) 0.05 (0.01–0.43)
 P value 0.005 0.006
Fetal/neonatal deaths
 Risk 10/134 (7.5 %) 1/90 (1.1 %) 0/65 (0 %)
 aORb (95 % CI) Reference group 0.10 (0–0.86) 0 (n/a)
 P value 0.03 0.03
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Discussion
While conducting a clinical trial comparing novel IPTp 
strategies in a high-transmission setting in Uganda with 
near-universal LLIN coverage, the unexpected oppor-
tunity arose to evaluate the additional impact of IRS on 
measures of malaria during pregnancy and adverse birth 
outcomes. In this setting, the period following protec-
tion with IRS was associated with a significantly lower 
incidence of symptomatic malaria and prevalence of 
parasitaemia during pregnancy. Reductions in parasite 
prevalence were observed among women randomized to 
either IPTp-SP or IPTp-DP, suggesting additional benefits 
of IRS when given along with LLINs and IPTp. Impor-
tantly, the period following protection with IRS was 
also associated with a significantly lower prevalence of 
malaria parasites in placental blood at the time of deliv-
ery, and a significantly lower risk of LBW, pre-term deliv-
ery, and fetal/neonatal deaths.
WHO recommends IRS as a central part of malaria 
control policy in Africa, but coverage rates have been low 
(<10  %) and have declined in recent years, possibly due 
to increased costs from spraying with non-pyrethroid 
insecticides [4]. Although IRS has been shown to be very 
effective in reducing vector densities and malaria mor-
bidity, particularly among children [10–18], no study has 
assessed its impact on malaria morbidity during preg-
nancy and birth outcomes. In eastern Uganda, rates of 
pyrethroid resistance among Anopheles mosquitoes and 
the prevalence of molecular markers of SP resistance 
among P. falciparum parasites are very high [6, 27]. This 
may explain the high parasite prevalence prior to IRS 
among pregnant women given LLINs and randomized 
to IPTp-SP, as well as the significant reduction in para-
site prevalence both during pregnancy and at delivery 
following implementation of carbamate-containing IRS. 
Although significant differences in placental histopathol-
ogy with increasing IRS exposure were not observed, it 
is possible that histopathologic changes may reflect early 
malaria exposure during pregnancy [28], as all women 
became pregnant prior to the implementation of IRS, 
and nearly 60 % of women had evidence of asymptomatic 
parasitaemia at enrolment [22].
Notably, IRS was associated with significant reductions 
in the risk of LBW and pre-term delivery, and no fetal or 
neonatal deaths occurred among women with >20 % IRS 
protection during pregnancy. LBW and pre-term deliv-
ery are multifactorial disorders, and relatively few inter-
ventions have been shown to improve these outcomes, 
especially in resource-limited settings [29–31]. It is pos-
sible that IRS may have led to improved birth outcomes 
by preventing placental infection by malaria parasites [2, 
32]. However, malaria in pregnancy is thought to con-
tribute to 20  % of LBW in sub-Saharan Africa [2], sig-
nificantly less than the reductions observed in this study, 
and improvements in birth outcomes were observed 
even in women without histological evidence of placen-
tal malaria. Furthermore, not all interventions that have 
been shown to prevent malaria infection during preg-
nancy have been shown to improve birth outcomes [33]. 
In addition to targeting Anopheles mosquitoes and pre-
venting malaria, IRS may be targeting other vectors such 
as, potentially, Aedes and culicine mosquitoes, argasid 
ticks and fleas that are capable of transmitting a variety 
of vector-borne pathogens [34] that could be associated 
with poor pregnancy outcomes. However, data on addi-
tional pathogens that may have been prevented by IRS 
were unavailable in this study.
There are several limitations to this study. As this was 
a pre-post observational study nested within a trial of 
IPTp, definitive causal inferences regarding the effect of 
IRS on pregnancy and birth outcomes cannot be drawn. 
Unmeasured confounders, including temporal and sea-
sonal changes, may have affected these results, although 
parasite prevalence prior to IRS was stable and high, 
lessening this possibility. There were also significant dif-
ferences between the IRS exposure groups, including a 
higher proportion of first pregnancies among women in 
the group not exposed to IRS during pregnancy. Multi-
variate adjustment and a secondary sensitivity analysis 
using propensity scores and inverse probability weight-
ing were performed to adjust for these differences, 
although it is possible that residual confounding remains. 
0 >0-20% >20-43%
1500
2000
2500
3000
3500
4000
Bi
rth
 W
ei
gh
t
IRS Protection Category
P=0.008
P=0.001
Fig. 3 Impact of IRS on birth weight. Shown are birth weights (clear 
circles) from infants born to mothers with no IRS exposure (n = 134), 
>0–20 % exposure (n = 90), and >20–43 % exposure (n = 65). Also 
shown are model adjusted means and 95 % CI (lines and error bars), 
and P values comparing birth weights between groups, adjusted for 
gravidity, gestation age study drugs started, wealth category, LAMP at 
enrolment, and treatment arm
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Furthermore, it is possible that given the timing of IRS 
within the context of this trial, a cohort effect may have 
led to these results, specifically with regard to birth out-
comes. However, women were enrolled over a period 
of 6  months, and delivered over a period of 6  months, 
reducing the possibility that this form of bias was respon-
sible for these results. Finally, due to sample size and 
study design, several aspects which would further help 
to inform policy were incompletely addressed. These 
include a determination of effect duration, as well as the 
relative contributions to protection from direct house-
hold versus community spraying.
Conclusions
The provision of IRS, in combination with LLINs and 
IPTp, was temporally associated with a reduction in 
the incidence of malaria during pregnancy, prevalence 
of malaria parasites during pregnancy and in placen-
tal blood, as well as improved birth outcomes. IRS may 
represent an important tool for combating malaria in 
pregnancy and for improving birth outcomes in malaria-
endemic settings. Additional and larger controlled evalu-
ations, including monitoring for malaria in pregnancy 
metrics in settings where IRS is currently being imple-
mented, are warranted to further assess this promising 
strategy, and to inform policy.
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